BMS Slashes Price of World’s First Oral TYK2 Allosteric Inhibitor Deucravacitinib by 86% via New Patient Access Platform

Recently, BMS announced that it will launchBMS Patient Connect Platform for Eligible PatientsProvideSotyktu(Deucravacitinib)，Discount exceeds 80%, and directlyDoor-to-door delivery.

DeucravacitinibRetail price: $6,828(30-day supply, daily dose of 6 milligrams)，The discount of DTP program will make the priceDropped to $950, equivalent to an 86% discount.

Source: Foreign media official website

In addition to reducing prices, BMS Patient Connect will also provide supportive resources for patients. And according to BMS,In the future, other drugs suitable for this model will also be added to the platform.。

Deucravacitinib is a global first-in-class tyrosine kinase 2（TYK2）Inhibitor,By selectively targeting TYK2 to inhibit the signaling of IL-23, IL-12, and IFN, these cytokines are key factors involved in the pathogenesis of various immune-mediated diseases.

September 2022,Deucravacitinib was first approved for marketing in the United States.In October 2023, the product entered the Chinese market.，Used for treatmentAdult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy. This May,Deucravacitinib New Indication Marketing Application Accepted by CDE.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb